Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Isogenica

Isogenica
2000 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$62.2K LATEST DEAL AMOUNT
3 INVESTORS
Description

Provider of antibody design and discovery services. The company's antibody design and discovery services specializes in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies, enabling people to maker use of both conventional technologies and proprietary capabilities.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • The Mansion
  • Chesterford Research Park, Essex, Saffron Walden
  • Little Chesterford CB10 1XL
  • England, United Kingdom

+44 01799 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Isogenica’s full profile, request a free trial.

Isogenica Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 11-Apr-2017 $62.2K 00.000 00.000 Completed Generating Revenue
4. Later Stage VC 30-Jun-2014 00.000 Completed Generating Revenue
3. Later Stage VC 29-Nov-2012 00.000 00.000 000.00 Completed Generating Revenue
2. Grant 08-May-2012 $9.2M $3.96M Completed Generating Revenue
1. Corporate 06-May-2008 $3.96M $3.96M 000.00 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Isogenica Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Ordinary .5 000,000 00.00 00.00 00 00.00 0.000
Ordinary .747 0,000,000 00.00 00.00 00 00.00 0.000
Ordinary .6 12,500,000 $0.15 $0.15 1x $0.15 21.84%
To view this company’s complete Cap Table, request access »

Isogenica Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000000 00000000 Corporate Backed or Acquired Cambridge, United Kingdom 00 000000000000
To view this company’s complete list of competitors, request access »

Isogenica Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Innovate UK Government Minority 000 0000 000000 0
European Union Seventh Framework Programme Government 000 0000 000000 0
KC Holding Corporation Minority 000 0000 000000 0

Isogenica Executive Team (7)

Name Title Board
Seat
Contact
Info
Emma Sceats Ph.D Chief Executive Officer
Guy Hermans Ph.D Chief Scientific Officer
Adam Collier Ph.D Director, Commercial Development

4 Former Executives

You’re viewing 3 of 7 executives. Get the full list »

Isogenica Board Members (7)

Name Representing Role Since Contact
Info
David Burns Self Board Member 000 0000
Göran Forsberg Ph.D Self Board Member 000 0000
Jan-Olof Lundin Self Chairman 000 0000
Niclas Eriksson Self Board Member 000 0000
Renny Leach Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »